# antibodies -online.com







Image



# Overview

Quantity:	100 μL
Target:	PIM1
Binding Specificity:	pTyr309
Reactivity:	Human, Mouse, Rat
Host:	Rabbit
Clonality:	Polyclonal
Conjugate:	This PIM1 antibody is un-conjugated
Application:	Western Blotting (WB), ELISA, Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p)), Immunohistochemistry (Frozen Sections) (IHC (fro))

# **Product Details**

Immunogen:	KLH conjugated synthetic phosphopeptide derived from human PIM1 around the phosphorylation site of Tyr218
Isotype:	IgG
Specificity:	This phosphorylation site is also referred to as Tyr218, as this is the position in Isoform 2 of this protein. This phosphorylation site is homologous to Tyr302 in Mouse and Tyr218 in Rat.
Cross-Reactivity:	Human, Mouse, Rat
Predicted Reactivity:	Dog,Cow,Sheep,Pig,Rabbit
Purification:	Purified by Protein A.

# **Target Details**

Target:	PIM1
Alternative Name:	PIM1 (PIM1 Products)
Background:	Synonyms: PIM, Serine/threonine-protein kinase pim-1, PIM1
	Background: Proto-oncogene with serine/threonine kinase activity involved in cell survival and
	cell proliferation and thus providing a selective advantage in tumorigenesis. Exerts its
	oncogenic activity through: the regulation of MYC transcriptional activity, the regulation of cell
	cycle progression and by phosphorylation and inhibition of proapoptotic proteins (BAD,
	MAP3K5, FOXO3). Phosphorylation of MYC leads to an increase of MYC protein stability and
	thereby an increase of transcriptional activity. The stabilization of MYC exerted by PIM1 might
	explain partly the strong synergism between these two oncogenes in tumorigenesis. Mediates
	survival signaling through phosphorylation of BAD, which induces release of the anti-apoptotic
	protein Bcl-X(L)/BCL2L1. Phosphorylation of MAP3K5, an other proapoptotic protein, by PIM1,
	significantly decreases MAP3K5 kinase activity and inhibits MAP3K5-mediated phosphorylation
	of JNK and JNK/p38MAPK subsequently reducing caspase-3 activation and cell apoptosis.
	Stimulates cell cycle progression at the G1-S and G2-M transitions by phosphorylation of
	CDC25A and CDC25C. Phosphorylation of CDKN1A, a regulator of cell cycle progression at G1,
	results in the relocation of CDKN1A to the cytoplasm and enhanced CDKN1A protein stability.
	Promote cell cycle progression and tumorigenesis by down-regulating expression of a regulator
	of cell cycle progression, CDKN1B, at both transcriptional and post-translational levels.
	Phosphorylation of CDKN1B,induces 14-3-3-proteins binding, nuclear export and proteasome-
	dependent degradation. May affect the structure or silencing of chromatin by phosphorylating
	HP1 gamma/CBX3. Acts also as a regulator of homing and migration of bone marrow cells
	involving functional interaction with the CXCL12-CXCR4 signaling axis.
Gene ID:	5292
UniProt:	P11309
Pathways:	Glycosaminoglycan Metabolic Process
Application Details	
Application Notes:	WB 1:300-5000
	ELISA 1:500-1000
	IHC-P 1:200-400
	IHC-F 1:100-500
	IF(IHC-P) 1:50-200

Application Details	
	IF(IHC-F) 1:50-200
	IF(ICC) 1:50-200
Restrictions:	For Research Use only
Handling	
Format:	Liquid
Concentration:	1 μg/μL
Buffer:	0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.
Preservative:	ProClin
Precaution of Use:	This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.


# Storage Comment:

Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Expiry Date: 12 months

# **Images**

Storage:



4 °C,-20 °C

# **SDS-PAGE**

Image 1. Lane 1: mouse brain lysates Lane 2: human colon carcinoma lysates probed with Anti PIM1(Tyr218) Polyclonal Antibody, Unconjugated (ABIN745058) at 1:200 in 4 °C. Followed by conjugation to secondary antibody at 1:3000 90min in 37 °C. Predicted band 45kD. Observed band size: 45kD.